Plasma Thermogram Parameters Differentiate Status and Overall Survival of Melanoma Patients.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE
    • Publication Information:
      Publication: 2021- : Basel, Switzerland : MDPI
      Original Publication: Toronto : Multimed, c1994-
    • Subject Terms:
      Melanoma*/pathology ; Skin Neoplasms*/pathology; Humans ; United States ; Calorimetry, Differential Scanning ; Prognosis
    • Abstract:
      Melanoma is the fifth most common cancer in the United States and the deadliest of all skin cancers. Even with recent advancements in treatment, there is still a 13% two-year recurrence rate, with approximately 30% of recurrences being distant metastases. Identifying patients at high risk for recurrence or advanced disease is critical for optimal clinical decision-making. Currently, there is substantial variability in the selection of screening tests and imaging, with most modalities characterized by relatively low accuracy. In the current study, we built upon a preliminary examination of differential scanning calorimetry (DSC) in the melanoma setting to examine its utility for diagnostic and prognostic assessment. Using regression analysis, we found that selected DSC profile (thermogram) parameters were useful for differentiation between melanoma patients and healthy controls, with more complex models distinguishing melanoma patients with no evidence of disease from patients with active disease. Thermogram features contributing to the third principal component (PC3) were useful for differentiation between controls and melanoma patients, and Cox proportional hazards regression analysis indicated that PC3 was useful for predicting the overall survival of active melanoma patients. With the further development and optimization of the classification method, DSC could complement current diagnostic strategies to improve screening, diagnosis, and prognosis of melanoma patients.
    • References:
      J Cutan Pathol. 2015 Apr;42(4):244-52. (PMID: 25727210)
      Front Mol Biosci. 2020 Jul 14;7:154. (PMID: 32760738)
      J Transl Med. 2012 Jul 09;10:85. (PMID: 22554099)
      Oncotarget. 2018 Jan 25;9(10):9391-9399. (PMID: 29507697)
      Methods. 2015 Apr;76:41-50. (PMID: 25448297)
      AAPS PharmSciTech. 2019 Mar 18;20(4):146. (PMID: 30887400)
      Cochrane Database Syst Rev. 2019 Jul 01;7:CD012806. (PMID: 31260100)
      Cancer. 2017 Feb 15;123(4):617-628. (PMID: 27768230)
      PLoS One. 2017 Nov 17;12(11):e0186398. (PMID: 29149219)
      Biochim Biophys Acta Gen Subj. 2018 Aug;1862(8):1701-1710. (PMID: 29705200)
      Dermatoendocrinol. 2011 Jul;3(3):205-10. (PMID: 22110781)
      J Natl Compr Canc Netw. 2021 Apr 1;19(4):364-376. (PMID: 33845460)
      J Pers Med. 2020 Dec 31;11(1):. (PMID: 33396529)
      Cancer Immunol Immunother. 2010 Feb;59(2):303-12. (PMID: 19672595)
      Front Med (Lausanne). 2021 Apr 16;8:642380. (PMID: 33937286)
      Diagn Pathol. 2015 Oct 26;10:195. (PMID: 26503349)
      Exp Mol Pathol. 2009 Jun;86(3):186-91. (PMID: 19146849)
      Biochim Biophys Acta. 2012 Dec;1820(12):1879-85. (PMID: 22903026)
      Life (Basel). 2022 Dec 01;12(12):. (PMID: 36556369)
      Biochim Biophys Acta. 2016 May;1860(5):981-989. (PMID: 26459005)
      Mol Carcinog. 2020 Jun;59(6):640-650. (PMID: 32232919)
      Neurosurgery. 2013 Aug;73(2):289-95; discussion 295. (PMID: 23624408)
      PLoS One. 2012;7(8):e43369. (PMID: 22912864)
      J Med Genet. 2021 Nov;58(11):760-766. (PMID: 32994281)
      Lab Invest. 2017 Sep;97(9):1063-1071. (PMID: 28737763)
      Anal Chem. 2011 Oct 15;83(20):7992-8. (PMID: 21928840)
      CA Cancer J Clin. 2017 Nov;67(6):472-492. (PMID: 29028110)
      Am J Pathol. 2003 Nov;163(5):1765-70. (PMID: 14578177)
      Acta Oncol. 2020 Jul;59(7):833-844. (PMID: 32285732)
      Cancers (Basel). 2019 Jul 19;11(7):. (PMID: 31331013)
      PLoS One. 2014 Jan 08;9(1):e84710. (PMID: 24416269)
      J Cutan Pathol. 2015 Nov;42(11):807-14. (PMID: 26239102)
      Sci Rep. 2017 Dec 1;7(1):16796. (PMID: 29196643)
      Med Hypotheses. 2020 Apr;137:109542. (PMID: 31901878)
      Cancers (Basel). 2021 Oct 23;13(21):. (PMID: 34771491)
    • Grant Information:
      R01 AI129959 United States AI NIAID NIH HHS; R21 CA187345 United States CA NCI NIH HHS; P30 CA016058 United States CA NCI NIH HHS; UL1 TR002733 United States TR NCATS NIH HHS
    • Contributed Indexing:
      Keywords: diagnosis; differential scanning calorimetry (DSC); melanoma; no evidence of disease (NED); overall survival (OS); thermogram
    • Publication Date:
      Date Created: 20230728 Date Completed: 20230731 Latest Revision: 20230819
    • Publication Date:
      20230819
    • Accession Number:
      PMC10378067
    • Accession Number:
      10.3390/curroncol30070453
    • Accession Number:
      37504313